The role of human epididymis secretory protein E4 in patients with endometrial cancer and premalignant endometrial lesions

Basit Öğe Kaydı
dc.contributor.authorYılmaz, Setenay Arzu
dc.contributor.authorAltınkaya, Sündüz Özlem
dc.contributor.authorKerimoğlu, Özlem Seçilmiş
dc.contributor.authorPekin, Aybike Tazegül
dc.contributor.authorAkyürek, Fikret
dc.contributor.authorİlhan, Tolgay Tuyan
dc.contributor.authorBenzer, Nilgün
dc.date.accessioned2020-03-26T19:43:08Z
dc.date.available2020-03-26T19:43:08Z
dc.date.issued2017
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractWe evaluated the concentrations of human epididymis secretory protein E4 (HE4) and Ca-125 in relation to clinicopathologic features in patients with endometrial cancer and premalignant endometrial lesions. Women with abnormal uterine bleeding (n=167) who underwent endometrial sampling were divided into four groups. Group 1: endometrial cancer (n=68), group 2: atypical endometrial hyperplasia (n=12), group 3: endometrial hyperplasia without atypia (n=39) and group 4: controls (n=48). Women with endometrial cancer exhibited higher concentrations of HE4 levels than controls (91.4pmol/L vs. 46.2pmol/L, p<0.001). HE4 levels were significantly higher in patients with lymphatic involvement, deep myometrial invasion, lymphovascular space involvement and non-endometrioid histology (p<0.001). The sensitivity, specificity, positive and negative predictive values for HE4 in detecting endometrial cancer were 72.7%, 84.4%, 80% and 78.4%, respectively. Preoperative HE4 levels are more elevated in women with endometrial cancer than those with benign endometrium as well as in women with prognostic high-risk factors with endometrial cancer. HE4 may be used as an additional marker in combination with other clinicopathologic features for planning the treatment.en_US
dc.identifier.doi10.3109/01443615.2016.1174199en_US
dc.identifier.endpage63en_US
dc.identifier.issn0144-3615en_US
dc.identifier.issn1364-6893en_US
dc.identifier.issue1en_US
dc.identifier.pmid28006994en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage58en_US
dc.identifier.urihttps://dx.doi.org/10.3109/01443615.2016.1174199
dc.identifier.urihttps://hdl.handle.net/20.500.12395/35609
dc.identifier.volume37en_US
dc.identifier.wosWOS:000395199200013en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTAYLOR & FRANCIS INCen_US
dc.relation.ispartofJOURNAL OF OBSTETRICS AND GYNAECOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectEndometrial canceren_US
dc.subjecthuman epididymis secretory protein E4en_US
dc.subjectendometrial hyperplasiaen_US
dc.subjectatypical endometrial hyperplasiaen_US
dc.subjectendometrial hyperplasia without atypiaen_US
dc.titleThe role of human epididymis secretory protein E4 in patients with endometrial cancer and premalignant endometrial lesionsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu